Study on Human Bioequivalence of Triprerelin Acetate for Injection
Status:
RECRUITING
Trial end date:
2025-09-04
Target enrollment:
Participant gender:
Summary
To investigate the pharmacokinetics of triprerelin acetate for injection and triprerelin acetate (Dufferin ) for injection of reference preparation in patients with prostate cancer by single intramusculodynamic injection in fasting state, and to evaluate the bioequivalence of the two formulations in fasting state.
Phase:
PHASE1
Details
Lead Sponsor:
The Affiliated Hospital of Qingdao University
Collaborators:
First Affiliated Hospital of Chengdu Medical College Hunan Cancer Hospital Shandong Cancer Hospital and Institute Shanxi Province Cancer Hospital The First Affiliated Hospital of Shanxi Medical University The Second Affiliated Hospital of Chongqing Medical University Yichang Central People's Hospital Yuncheng Central Hospital Zibo Central Hospital